List of Excipients in Branded Drug JENCYCLA

Generic Drugs Containing JENCYCLA

Company	Ingredient	NDC	Excipient
LUPIN LIMITED	norethindrone	57297-877	ANHYDROUS LACTOSE
LUPIN LIMITED	norethindrone	57297-877	D&C YELLOW NO. 10
LUPIN LIMITED	norethindrone	57297-877	FD&C BLUE NO. 1
LUPIN LIMITED	norethindrone	57297-877	MAGNESIUM STEARATE
LUPIN LIMITED	norethindrone	57297-877	POVIDONE
LUPIN LIMITED	norethindrone	57297-877	SODIUM STARCH GLYCOLATE TYPE A POTATO
Lupin Pharmaceuticals Inc	norethindrone	68180-877	ANHYDROUS LACTOSE

What are the Most Frequently-Used Excipients in JENCYCLA?

# Of NDCs	Excipient
2	ANHYDROUS LACTOSE
2	D&C YELLOW NO. 10
2	FD&C BLUE NO. 1
2	MAGNESIUM STEARATE
2	POVIDONE
2	SODIUM STARCH GLYCOLATE TYPE A POTATO

Jencycla Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Jencycla is a norethindrone 0.35 mg progestin-only oral contraceptive supplied as a 28-tablet regimen. Its commercial opportunity is driven by formulation efficiency, supply reliability, tolerability, packaging, and differentiated patient access rather than by an innovative active ingredient or an identifiable brand-specific patent barrier. The core formulation uses conventional, low-cost tablet excipients, leaving room for manufacturers to compete through excipient optimization, direct compression, improved robustness, and alternative presentation formats.

What is Jencycla and how is it supplied?

Jencycla contains norethindrone, a synthetic progestin, at 0.35 mg per tablet. It is indicated for the prevention of pregnancy and is administered continuously, with one tablet taken at the same time every day. The 28-tablet pack does not include a tablet-free interval [1].

Attribute	Jencycla
Active ingredient	Norethindrone
Strength	0.35 mg
Dosage form	Immediate-release oral tablet
Regimen	One tablet daily for 28 days, continuously
Therapeutic class	Progestin-only oral contraceptive
Estrogen	None
Primary users	Patients seeking or requiring estrogen-free contraception
Regulatory pathway	Abbreviated New Drug Application-type generic product
Commercial category	Prescription generic oral contraceptive

Norethindrone-only tablets are used by patients who may avoid estrogen because of breastfeeding, migraine with aura, thromboembolic risk factors, smoking-related concerns, or estrogen intolerance. The product competes with other norethindrone tablets, drospirenone-only pills, combined oral contraceptives, long-acting reversible contraceptives, injectables, implants, and emergency contraceptive products.

What excipients are used in Jencycla?

The Jencycla label identifies conventional tablet excipients, including lactose monohydrate, corn starch, magnesium stearate, povidone, and sodium starch glycolate [1]. These excipients support powder flow, granulation, binding, lubrication, and tablet disintegration.

Excipient	Likely functional role	Commercial relevance
Lactose monohydrate	Diluent and tablet mass builder	Low cost; established oral safety record; relevant to lactose-sensitive users
Corn starch	Diluent and disintegration aid	Supports tablet breakup and processing
Povidone	Binder	Improves granule strength and content uniformity
Sodium starch glycolate	Superdisintegrant	Supports rapid tablet disintegration
Magnesium stearate	Lubricant	Controls ejection force and tooling adhesion

Because the norethindrone dose is only 0.35 mg, the excipient system controls much of the tablet’s physical behavior. Low-dose products require effective content-uniformity controls because the active pharmaceutical ingredient represents a very small fraction of total tablet weight.

The formulation is conventional and does not appear to rely on a proprietary delivery system, modified-release mechanism, lipid carrier, enteric coating, or complex solid-dispersion platform. The principal technical risks are blend uniformity, segregation, lubrication sensitivity, tablet hardness, disintegration, dissolution, and stability.

How should manufacturers design an excipient strategy for norethindrone 0.35 mg?

A commercial formulation strategy should begin with dose uniformity and manufacturing reproducibility. The preferred platform is a robust, immediate-release tablet that can be produced by wet granulation, dry granulation, or a validated direct-compression process.

Low-dose content uniformity

Norethindrone at 0.35 mg creates a high dilution ratio. A manufacturer should evaluate:

• Ordered addition of norethindrone to a carrier or premix.
• Geometric dilution during blending.
• Particle-size matching between norethindrone and major excipients.
• Blend segregation during transfer and hopper filling.
• Sampling plans that detect localized concentration variability.
• In-process weight and assay controls.

Lactose, microcrystalline cellulose, mannitol, dibasic calcium phosphate, and starch-based carriers can all be evaluated as diluents. The optimal choice depends on bulk density, particle morphology, electrostatic behavior, and compatibility with the selected process.

Direct compression

Direct compression can reduce manufacturing steps, solvent use, drying time, and equipment requirements. It is commercially attractive where the powder blend has adequate flow and compressibility.

A direct-compression platform could use spray-dried lactose, microcrystalline cellulose, coprocessed excipients, or directly compressible mannitol. The principal development risks are segregation and poor content uniformity caused by the low drug load.

Wet granulation

Wet granulation can improve blend uniformity and reduce segregation. Povidone or a comparable binder can produce stronger granules and more predictable tablet weight. The tradeoff is a longer process, higher energy use, and added exposure to water and heat.

A wet-granulation process may be preferable when the active ingredient has poor flow or when direct-compression trials show unacceptable assay variability. It also gives manufacturers more control over granule density and downstream tablet compression.

Disintegration and dissolution

Sodium starch glycolate is an established superdisintegrant for immediate-release tablets. Crospovidone and croscarmellose sodium are potential alternatives. A formulation change should preserve rapid tablet breakup and comparable dissolution across relevant pH conditions.

The most commercially useful differentiation is unlikely to be a dramatic release-rate claim. The opportunity is a smaller, less friable, more robust tablet that maintains rapid dissolution and improves handling in packaging, pharmacies, and patient use.

What formulation patents protect Jencycla?

Jencycla is a generic norethindrone tablet rather than a new molecular entity. Publicly available product information does not identify a proprietary excipient platform or delivery technology associated with the product [1].

Potential patentable areas for a competing product would include:

1. A specific low-dose blend that improves norethindrone content uniformity.
2. A novel particle-engineering process for norethindrone.
3. A composition that reduces degradation or impurity formation.
4. A taste-masked or orally disintegrating formulation.
5. A packaging system that improves moisture or light protection.
6. A combination of excipients that improves tablet robustness without delaying dissolution.
7. A manufacturing process that achieves narrower assay variability.

A patent directed only to a conventional combination of lactose, starch, povidone, sodium starch glycolate, and magnesium stearate would face meaningful obviousness and enablement challenges. Stronger patent positions would require comparative data showing an unexpected technical effect, such as materially improved content uniformity, stability, dissolution, or manufacturability.

When does Jencycla lose exclusivity?

Jencycla is already marketed as a generic prescription product. The commercial exclusivity analysis therefore differs from that of a branded new drug.

Exclusivity category	Jencycla assessment
New chemical entity exclusivity	Not applicable
Five-year new-drug exclusivity	Not applicable to the generic product
Three-year new clinical investigation exclusivity	Not identified for the Jencycla product
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No Jencycla-specific period identified
Orange Book patent exclusivity	No proprietary Jencycla patent estate identified in the public product information
Generic competition	Permitted subject to FDA approval requirements

FDA Orange Book listings determine whether patents are formally listed against a specific approved product. For a conventional norethindrone generic, the principal competitive barriers are usually regulatory approval, bioequivalence, manufacturing economics, quality systems, supply continuity, and payer access rather than product-specific patent protection [2].

What is the Orange Book status of Jencycla?

The Orange Book is the controlling FDA source for approved drug products, therapeutic equivalence evaluations, and listed patents [2]. Jencycla should be assessed at the product and application level because generic products may appear under different applicants, strengths, trade names, or reference-product relationships.

The practical conclusion is that an entrant should not assume a Jencycla-specific patent barrier based solely on the trade name. A full diligence review should distinguish:

• Patents listed against the reference norethindrone product.
• Patents listed against a particular applicant’s formulation.
• Unlisted manufacturing or formulation patents.
• Process patents held by excipient or API suppliers.
• Regulatory exclusivity that is separate from patent rights.

For a conventional immediate-release norethindrone tablet, a Paragraph IV strategy would be relevant only if an ANDA applicant faces a listed patent that has not expired or been disclaimed. If no relevant patent is listed, the applicant may pursue a standard certification pathway rather than a Paragraph IV certification.

What generic entry risks exist for Jencycla?

Generic entry risk is structurally high because norethindrone 0.35 mg is an established active ingredient in a conventional oral dosage form. A potential entrant would not need to reproduce the Jencycla trade name or copy every excipient. It would need to demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product under FDA requirements [3].

Key entry risks include:

• Failure to achieve content uniformity at the 0.35 mg strength.
• Dissolution differences caused by excipient substitution.
• Tablet weight variation.
• Inadequate stability under accelerated conditions.
• Failure to demonstrate acceptable impurity control.
• Manufacturing-site inspection findings.
• Supply disruptions involving norethindrone API.
• Packaging changes that affect shelf life.
• Labeling and medication-guide compliance.

Because the product is low dose and immediate release, formulation development may be technically manageable, but commercial launch still depends on cost of goods, approved manufacturing capacity, and distribution access.

Which excipient substitutions offer the strongest commercial opportunity?

The most practical opportunities are substitutions that lower cost, improve supply security, or create measurable manufacturing benefits without changing the product’s immediate-release profile.

Opportunity	Candidate approach	Commercial value
Lactose reduction	Replace or partially replace lactose with microcrystalline cellulose or mannitol	Expands use among lactose-sensitive patients and diversifies supply
Direct compression	Use spray-dried lactose, microcrystalline cellulose, or coprocessed excipients	Reduces process steps and manufacturing cost
Improved disintegration	Evaluate crospovidone or croscarmellose sodium	Supports rapid tablet breakup and process flexibility
Better tablet robustness	Optimize binder and granulation endpoint	Reduces breakage, chipping, and packaging loss
Smaller tablet	Increase excipient compactability and reduce total tablet weight	Improves swallowability and patient acceptability
Moisture control	Use moisture-protective blister or bottle systems	Improves stability and distribution resilience
Vegan or allergen-positioned product	Review animal-derived and allergen-relevant raw materials	Supports selected pharmacy and institutional channels
Global formulation platform	Develop a common core formula with market-specific packaging	Reduces development and supply complexity

Lactose-free positioning could be commercially useful, but it would not by itself establish a protected market. The value would depend on validated patient need, pharmacy channel access, and an approved label that supports the formulation claim.

What patient-facing dosage-form opportunities exist?

Jencycla is a conventional swallowed tablet. Alternative dosage forms could create more meaningful differentiation than minor changes to tablet excipients, although each would require a separate regulatory strategy.

Orally disintegrating tablet

An orally disintegrating norethindrone tablet could target patients with swallowing difficulty or those seeking discreet administration. Mannitol, crospovidone, microcrystalline cellulose, and flavor systems could support this design.

The main technical issues would be taste, friability, moisture sensitivity, packaging, and rapid disintegration. Norethindrone’s hormonal activity makes taste masking important because an uncoated tablet may have unacceptable mouthfeel.

Smaller tablet

A lower-weight tablet could improve swallowability. Since the active dose is very small, the main limitation is not drug mass but the quantity of functional excipients needed for manufacturability. A high-compactability excipient system could reduce tablet size without compromising assay uniformity.

Blister packaging

Calendarized blister packaging could support adherence to the continuous 28-day regimen. It also provides unit-dose protection and can reduce handling losses. Packaging, rather than excipient composition, may provide the most immediate commercial differentiation for a generic manufacturer.

How does Jencycla compare with other progestin-only contraceptives?

Product type	Active ingredient	Formulation opportunity	Competitive distinction
Jencycla and other norethindrone tablets	Norethindrone 0.35 mg	Conventional immediate-release tablet	Established, low-cost oral option
Drospirenone-only tablet	Drospirenone 4 mg	Immediate-release tablet with a different dosing cycle	Newer progestin-only oral alternative
Levonorgestrel intrauterine system	Levonorgestrel	Long-acting intrauterine delivery	Extended duration and low adherence burden
Etonogestrel implant	Etonogestrel	Subdermal implant	Multi-year contraception
Depot medroxyprogesterone acetate	Medroxyprogesterone acetate	Injectable suspension	Periodic rather than daily administration

Jencycla’s main advantages are low manufacturing complexity, oral administration, and an estrogen-free profile. Its principal disadvantage is the requirement for strict daily adherence. An excipient strategy can improve tablet handling and acceptability, but it cannot eliminate the adherence burden inherent in daily oral dosing.

What manufacturing and intellectual-property barriers affect entry?

The main manufacturing barrier is reliable production of a low-dose tablet at scale. The process must control assay uniformity across blending, granulation, compression, coating if used, and packaging.

Relevant IP exposure may arise from:

• Norethindrone API manufacturing processes.
• Crystalline or polymorphic forms of norethindrone.
• Particle-size control methods.
• Specific low-dose tablet compositions.
• Taste-masking systems.
• Orally disintegrating formulations.
• Moisture-barrier packaging.
• Manufacturing processes with defined blending or granulation conditions.

A generic manufacturer can often avoid composition patents through excipient substitution, provided the resulting product meets pharmaceutical equivalence and bioequivalence requirements. Process patents require a separate freedom-to-operate analysis because they may apply even when the final tablet composition differs.

What licensing opportunities exist for Jencycla-related excipients?

The most commercially relevant licensing opportunities are likely to involve excipient platforms rather than the Jencycla brand itself.

Potential partners include:

• Excipient manufacturers with directly compressible or coprocessed systems.
• Suppliers of low-dose uniformity premixes.
• Packaging companies with high-barrier blister technology.
• Contract development and manufacturing organizations.
• API manufacturers with secure norethindrone supply.
• Digital adherence companies supporting prescription contraception.

A licensing agreement could combine a proprietary excipient system with manufacturing know-how, analytical methods, and supply commitments. The strongest commercial case would require measurable benefits such as lower tablet weight, lower rejection rates, longer shelf life, reduced manufacturing cycle time, or improved dissolution robustness.

What is the regulatory status of a reformulated Jencycla product?

A material excipient change would normally require development under an ANDA or an appropriate supplemental pathway, depending on the product, applicant, and extent of the change. FDA review would focus on pharmaceutical equivalence, bioequivalence where applicable, stability, dissolution, impurities, manufacturing controls, and labeling [3].

A new dosage form, such as an orally disintegrating tablet, would present a larger regulatory and development burden than a conventional excipient substitution. The product may still be eligible for an ANDA if it meets the relevant reference-product requirements, but a novel route, release profile, or clinical claim could alter the regulatory pathway.

Excipient selection must also consider FDA’s Inactive Ingredient Database, prior levels of use, route of administration, maximum daily exposure, and population-specific tolerability [4].

Key Takeaways

• Jencycla is a 0.35 mg norethindrone immediate-release progestin-only tablet.
• Its formulation uses conventional excipients: lactose monohydrate, corn starch, povidone, sodium starch glycolate, and magnesium stearate.
• The main technical challenge is low-dose content uniformity, not complex drug delivery.
• Commercial differentiation is strongest in direct compression, tablet-size reduction, lactose-free positioning, packaging, and supply reliability.
• Jencycla does not present an obvious proprietary excipient or delivery platform.
• Generic-entry risk is high because norethindrone tablets are established products and the formulation is conventional.
• Paragraph IV risk depends on current Orange Book listings and relevant patents, not on the Jencycla trade name alone.
• Stronger formulation patents would require demonstrated technical advantages over conventional low-dose tablet systems.
• The most attractive licensing targets are excipient platforms, contract manufacturing, API supply, and adherence-support technologies.

FAQs

Can a lactose-free norethindrone 0.35 mg tablet compete with Jencycla?

Yes. A manufacturer could replace lactose with microcrystalline cellulose, mannitol, or another suitable diluent, subject to formulation, stability, dissolution, and regulatory requirements.

Is Jencycla protected by a formulation patent?

Public product information does not identify a proprietary Jencycla formulation patent. Current FDA Orange Book records and separate patent databases control the formal patent analysis.

Could an orally disintegrating norethindrone tablet receive FDA approval?

Potentially. The applicant would need to establish pharmaceutical equivalence or another appropriate regulatory basis, demonstrate performance and stability, address taste and packaging, and satisfy FDA review requirements.

Does changing magnesium stearate create a new commercial product?

Not necessarily. Replacing or adjusting the lubricant may be a routine formulation change, but the applicant must show that the change does not adversely affect manufacturability, dissolution, assay uniformity, stability, or bioequivalence.

Which excipient offers the greatest opportunity for product differentiation?

No single excipient is likely to create a durable advantage by itself. The strongest opportunity is an integrated platform combining low-dose uniformity, reduced tablet size, robust compression, rapid disintegration, and protective packaging.

References

1. DailyMed. (n.d.). Jencycla: Norethindrone tablet, 0.35 mg prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
3. U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products.
4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.